Transcranial direct current stimulation attenuates the chronic pain of osteoarthritis in rats via the top-down modulation

Xinhe Li
The First Affiliated Hospital of Xi’an Jiaotong University

Zhe Liu
The First Affiliated Hospital of Xi’an Jiaotong University

Fei Mao
The First Affiliated Hospital of Xi’an Jiaotong University

Yan Li
The First Affiliated Hospital of Xi’an Jiaotong University

Xiaoning Di
The First Affiliated Hospital of Xi’an Jiaotong University

Cuixia Shang
The First Affiliated Hospital of Xi’an Jiaotong University

Jin Qiao (✉ qiaojn123@163.com)
The First Affiliated Hospital of Xi’an Jiaotong University

Research Article

Keywords: osteoarthritis, transcranial direct current stimulation, chronic pain, NMDAR2B receptors

Posted Date: April 7th, 2023

DOI: https://doi.org/10.21203/rs.3.rs-2735703/v1

License: ☕ ⚖ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose

Osteoarthritis (OA) has been the common cause to lead to chronic pain. Numerous studies have demonstrated that transcranial direct current stimulation (tDCS) can revert maladaptive changes and relieve chronic pain. TDCS is effective in the treatment of a number of chronic pain conditions, but the top-down analgesic mechanism involved is still unclear. This study observed the analgesic effects of tDCS and the changes of NMDA receptors levels in the spinal cord after tDCS treatment in rats to explore the top-down analgesic mechanism of tDCS.

Methods

Monosodium iodoacetate (MIA) was injected into the ankle joint of rats to establish OA chronic pain model. After 21 days, the rats received tDCS for 14 consecutive days (20 min/day). As indicators of mechanical allodynia and thermal hyperalgesia, we used Von Frey test and hot plate test to assess the pain-related behaviors at different time points. Western blot and Immunohistochemistry were performed to observe the expression level of NMDAR2B in the spinal cord after tDCS treatment.

Results

After MIA injection, rats developed apparent mechanical hyperalgesia and thermal hyperalgesia. However, the pain-related behaviors of rats were significantly improved after tDCS treatment. In addition, the expression of NMDAR2B and the proportion of positive stained cells of NMDAR2B were reversed by tDCS treatment.

Conclusion

The results demonstrated that tDCS can attenuate OA-induced chronic pain in rats via reducing NMDAR2B expressions in the spinal cord. We believe that this may be the result of tDCS participating in the top-down modulation of pain pathway in the endogenous analgesic system.

Introduction

Osteoarthritis (OA) is the most common chronic degenerative joint disease\(^1\). Pain is the main symptom of OA, as well as the most relevant cause of disability and poor quality of life in the affected patients\(^2\). Currently, medical treatment often provided a limited improvement with processive pain and may also lead to lots of adverse effects over time\(^3,4\). The joint replacement operation is considered to be an
effective surgical intervention to solve OA pain, but studies have found that 20% of patients still have pain after joint replacement 5,6.

The mechanism of OA pain is complex, involving pain sensitization and the change in endogenous analgesic system 7,8. Studies showed there are several pathways from prefrontal areas and the ACC to the periaqueductal gray area (PAG), which may serve as a framework for tuning somatosensory information at the spinal cord level 9,10. The periaqueductal gray (PAG)-rostral ventromedial medulla (RVM)-spinal dorsal horn (DH) pathway was considered to be the key in endogenous analgesic system 11. The PAG receives the nociceptive information from the spinal cord DH, and it projects antinociceptive transmission to the RVM and lower brainstem, then the RVM projects the information to the spinal cord DH 12,13. Previous research has found N-methyl-D-aspartate (NMDA) receptors may contribute to the development of pain behavior 14. Moreover, in four NMDA receptors, the NR2B-containing NMDA receptor played an essential role in pain regulation, and it was considered one of the best potential target of pain 15–17.

Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that has been used to treat chronic disorders 18. TDCS regulates neuronal excitability by applying direct current to the scalp using two electrodes. Anodal stimulation enhances the excitability and cathodal stimulation decreases the excitability 19. Some studies have found that tDCS may modulate pain pathway through endogenous analgesic system 20,21. Studies have indicated that electrical stimulation in the cerebral cortex is able to modulate remote areas of the neuroaxis, such as the brainstem and the spinal cord 22. This exogenous stimulus may use similar pathways involved in the top-down modulation found across sensory systems 23. In our previous study, we demonstrated that tDCS can alleviate OA-induced chronic pain in rats by modulating the expression of NMDA receptors in PAG to play an analgesic role 24. However, whether the analgesic effect of tDCS can work in the spinal cord by top-down modulation is still unclear.

The purpose of this study is to explore the mechanism of top-down modulation of tDCS. If the analgesic mechanism of tDCS in the spinal cord is explored clearly, it will be very helpful to clarify the top-down modulation of tDCS.

**Materials And Methods**

**Ethics statement**

Sprague–Dawley rats (n = 40, weight 200 ± 20 g) were provided by the Experimental Animal Center. All the rats were housed in animal facilities with sufficiently controlled temperature (24 ± 1°C) and humidity (50–60%) under a 12/12-h light/ dark cycle and had access to chow and water. All procedures were strictly performed in accordance with recommendations from the Guide for the National Institutes of Health for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 2011). All animal
experiments were approved by the Ethics Committee of the Qingdao University (The approval number: NO. 20200901SD4520210601004) and were performed in accordance with the ethical criteria contained in the bylaws of the committee. Meanwhile, all methods reported in this study were in accordance with ARRIVE guidelines.

**Experimental design**

There is a habituation period of one week for rats. After the adaptation period, the rats were randomly divided into four groups: Sham group, MIA group, MIA + tDCS group and MIA + StDCS group. Except for the Sham group, the rats in other three groups were injected with MIA into the articular cavity. Then the tDCS and StDCS sessions were applied for 14 days (20 min/day) after 21 days of MIA injection. (Fig. 1)

**Animal model**

OA chronic pain model was induced after the rats were light anesthetized with 5% isoflurane in O2, then rats were injected with 60 µl 80mg/ml monosodium iodoacetate (MIA, Sigma, USA) into the left ankle joint cavity. As normal control group, the rats in Sham group were injected with saline into the identical parts.

**Transcranial direct current stimulation (tDCS)**

After 21 days of MIA injection, the rats in MIA + tDCS and MIA + StDCS groups were subjected to a constant direct current of 0.5 mA (20 minutes/day) for 14 consecutive days. We used bandages to bind rats’ limbs to prevent them from moving after the rats were transiently anesthetized by 5% isoflurane in O2. In order to fit the rats’ heads, we reduced the size of the electrodes to 1.5 cm$^2$ and maintained the stimulation parameters at 0.33mA/cm$^2$ with no lesions for the brain. In addition, the rats’ heads were shaved for better adherence before application. The anodal electrode was placed between the ears, on the neck of the rat (parietal cortex) and the cathodal electrode was positioned at the midpoint between the lateral angles of both eyes (supraorbital area). After being positioned, the electrodes were fixed onto the head using adhesive tape. Sham-stimulated (StDCS) rats underwent similar procedures, but the stimulator was turned off throughout the experiments.

**Behavioral testing**

**Mechanical alldynia**

In order to assess mechanical alldynia, the Von Frey hair (North Coast, USA) based on the up-down method has been adopted. Behavioral test was performed in a blinded manner, the observer was not clear about the grouping in advance. Before testing, rats were placed individually on a suspended wire cage with a mesh-bottom and allowed to acclimate for 10 min. A series of Von Frey filaments, with calibrated bending force ranging from 0.16 to 26 g, were then applied perpendicularly to the plantar surface of the left hind paw. The tests invariably began with 2g, and each hair was applied 5 times with an interval of 5 minutes between the two stimuli. For the mechanical stimulation, retreat or paw licking
after stimulation is considered a positive reaction. If the paw is not retracted, the next stronger stimulus is applied. Instead, a weaker stimulus was chosen. If we observed positive responses from a particular hair 3 out of the five consecutive applications, the value of a particular hair in that gram was considered to be the paw withdrawal threshold (PWT). According to the up-down method, the 50% response threshold was interpolated using the formula: $50\%$ g threshold = $(10^{[X_f+Kl]})/10,000$. Ultimately, the measurements were averaged in each group.

**Thermal hyperalgesia**

All rats were exposed to a hot plate (HP) for 5 min to adapt to the hot plate 24 h before testing. On the test day, the temperature of the hot plate was maintained at $55 \pm 1^\circ C$. The rats were placed in glass funnels on the heated surface, and the time in seconds for quickly pulling, licking, or contracting its extremities was recorded as the paw withdrawal latency (PWL).

**Western blot analysis**

Rats ($n = 3$/group) were deeply anesthetized and sacrificed. The spinal cord tissues were quickly removed and stored at -80°C. These tissues were homogenized in a mixture of RIPA lysis buffer containing proteinase inhibitor, and centrifuged at 4°C at 12,000 rpm for 15 min in order to collect the supernatants. Protein content was quantified using a BCA protein assay kit (Solarbio, China). After that, each sample, containing 20 µg protein, was loaded into 10% SDS-polyacrylamide gels for electrophoresis, then transferred to a polyvinylidene difluoride (PVDF) membrane (Sigma, USA). The membranes were blocked with 5% non-fat dry milk in TBST at room temperature for 2 hours, and incubated with the following primary antibodies at 4°C overnight: NMDAR2B (diluted 1:5000, Abcam) or GAPDH (diluted 1:5000, Abways). Next, the membranes were incubated with HRP-labeled goat anti-rabbit IgG secondary antibody (diluted 1:5000, Bioss) for 2 hours after washing with TBST. Each membrane was washed three times with TBST and visualized using an enhanced chemiluminescence ECL reagent (Millipore, USA). Images were analyzed by Image J software.

**Immunohistochemistry analysis**

The rats in four groups ($n = 4$/group) were deeply anesthetized and then perfused transcardially with cold saline followed by 4% cold paraformaldehyde (pH 7.4). Subsequently, the spinal cord tissues were quickly removed and placed in the perfusion fixative (4°C) for 24 h. Paraffin-embedded sections of the spinal cord were cut into 5-µm-thick sections and treated with 0.3% Triton X-100 and 3% H$_2$O$_2$ in PBS for 1 h, and processed for 2 h in 5% normal goat serum, then incubated overnight with primary antibodies at 4°C at the following dilutions: anti-NR2B. This was followed by incubation with secondary antibodies (diluted 1:1000, Abcam) for 1 h after washing with PBS and subsequently reacted with DAB for color development. Next, these sections were redyed with hematoxylin after flushing with running water for 30 minutes, then dehydrated through a series of ethanol solutions, cleared in xylene. Finally, images were obtained on a confocal Olympus Fluoview IX73 microscope.

**Statistical analysis**
All results were presented as Mean ± SEM and analyzed by GraphPad Prism 8.0 software (GraphPad Software, CA, USA). One-way ANOVA were used for analyzing the differences between the groups for the Western blot and Immunohistochemistry staining. Two-way repeated measures of ANOVA (two-way RMANOVA) was used to test the differences in pain thresholds. For all comparisons P < 0.05 was considered significant.

Results

PWT and PWL were significantly decreased after MIA injection in rats

Before MIA injection, there was no significant difference in PWT and PWL between the four groups. The tests of pain-related behaviors after MIA injection showed that compared with the Sham group, the PWT and PWL of MIA-induced OA rats were significantly decreased in the whole process (Fig. 2A and 2B). These results indicated that MIA may induce mechanical allodynia and thermal hyperalgesia in rats.

The tDCS treatment improved the pain-related behaviors

21 days after MIA injection, the rats received tDCS or StDCS treatment. The analysis of behavioral testing showed that compared with the MIA group, the PWT in MIA + tDCS group dramatically decreased on 14 days after tDCS treatment. Similarly, compared with the MIA group, the PWL in MIA + tDCS group was obviously reversed by tDCS treatment. Moreover, there was no obvious difference for PWT and PWL between the MIA + StDCS and the MIA groups (Fig. 3A and 3B). Our findings suggested that the tDCS treatment may have a significant analgesic effect on chronic pain induced by MIA in rats.

The tDCS treatment down-regulated NMDAR2B expression in the spinal cord of rats

The Western blot results indicated that compared with the day before MIA injection, there was a remarkable increase in NMDAR2B level on days 7, 14, and 21 after MIA injection (Fig. 4A). In addition, the Fig. 4B showed that tDCS treatment substantially down-regulated the expression of NMDAR2B in the spinal cord compared with the MIA group. Furthermore, there was no significant difference between the MIA + StDCS and the MIA groups. The result analysis of Immunohistochemistry also suggested that the proportion of positive stained cells significantly decreased after tDCS treatment and there was no significant difference in the proportion of positive stained cells between the MIA and MIA + StDCS group. (Fig. 5). The results of Western blot and Immunohistochemistry showed that the expression of NMDAR2B in the spinal cord increased after MIA injection. TDCS treatment could down-regulate the expression of NMDAR2B.

Discussion
In the past research, we found tDCS can alleviate OA-induced chronic pain in rats by modulating the expression of NMDA receptors in PAG. The study illustrates the mechanism of tDCS at the top of the central nervous system (CNS), but how tDCS works at the bottom of the CNS is still unclear. Therefore, the current study aimed to explore the mechanism of top-down modulation of tDCS in the spinal cord. Our results showed that tDCS reverted mechanical allodynia and thermal hyperalgesia, it also decreased the NMDAR2B levels in spinal cord. We concluded that tDCS can modulate the expression of NMDA receptors in spinal cord and alleviate chronic pain. This research may be an important reference for clarifying the top-down modulation of tDCS.

In the current study, a 20-min session of tDCS treatment for 14 consecutive days was applied to the rats on day 21 after MIA injection. We observed that compared with the MIA group, the PWT of the MIA + tDCS group gradually increased and there was significant difference on the 14th day after the tDCS treatment. In addition, the results of pain-related behaviors showed that the significant improvement of PWL in MIA + tDCS group occurred on the 7th day after the treatment. There is a difference in the analgesic response of tDCS, which may be related to the fibers activated by mechanical and thermal stimulation. Thermal nociception is mediated by C- and Aδ-fibers and mechanical response is mediated by Aβ fibers. Our results showed that tDCS relieved OA-induced mechanical allodynia and thermal hyperalgesia, but there may be differences in treatment time for alleviating pain.

Neurotransmission of pain from the periphery to the cortex relies upon integration and signal processing within the spinal cord, brain stem and via the thalamus to specific areas of the cortex. The anterior cingulate cortex and insular cortex are integral to nociception. Recent work has shown that glutamate is the major fast excitatory transmitter within these structures, which is also considered to be involved in the development of pain behavior. A previous study found that tDCS has two effects, the short-term effects are mediated by ionic channel modulation, the long-term effects are mediated by NMDA receptors. N-methyl-D-aspartate (NMDA) receptors play a pivotal role in synaptic transmission and neural plasticity. NMDA receptors containing the NR2B subunit constitute a major population in the adult mammalian forebrain and spinal cord. Research found that the expression of NMDAR subunit 2B (NMDAR2B) in the in spinal dorsal horn (DH) is higher in mice models of diabetic neuropathy. In addition, Fifteen Aprila Fajrin et al. suggested that it can significantly ameliorated hyperalgesia and allodynia in mice model of PDN by reducing the expression of TRPV1 and NMDAR2B in the spinal cord. In our research, The expression of NMDAR2B increased significantly during the establishment of OA pain model, accompanied by the remarkable increase of PWT and PWL. After tDCS treatment, the expression of NMDAR2B decreased in the spinal cord of rats, and the pain-related behaviors also improved significantly.

In this study, the expression of NMDAR2B decreased after tDCS treatment. We believed that this result may be related to the changes of NMDA receptors in the top central nervous system. Studies have confirmed that selectively over-expressing the NR2B subunit protein in the mouse anterior cingulate cortex/insular cortex enhanced responsiveness to subsequent peripheral injection of inflammatory
stimuli (chronic pain model), whereas no effect on acute pain models was reported. There is also a growing body of evidence to suggest opioid systems in the midbrain are activated during tDCS and that patients receiving tDCS may require less opioid-analgesia. The analgesic effects of tDCS have also been enhanced when used alongside conditioned pain modulation (CPM) paradigms in healthy subjects suggesting bottom-up changes in supraspinal sites may be involved. It is therefore possible that tDCS applied over the primary motor cortex may be involved in the top-down modulation of pain processing at the spinal level.

Classically, tDCS effects have been attributed to interactions between prosencephalon regions, such as the primary motor cortex, dorsal lateral prefrontal cortex, and cingulate cortex. However, tDCS effects may involve projections to remote area, such as the periaqueductal gray area, which is part of the descending system to the spinal cord. More and more studies believed that tDCS could be effective in the direct contact area of the electrode and play a role in the distance. In our previous study, we chose M1 as the stimulation site of tDCS and observed the changes of NMDA receptor in periaqueductal gray (PAG). It is believed that the stimulation of tDCS in M1 region can activate contiguous regions such as PAG. Other studies have also found tDCS delivered to the cerebral cortex is able to reduce pain sensitivity and modulate neuronal changes in the spinal cord and brainstem, probably by top-down systems. Combined with our previous studies, we believe that there is a top-down modulation of tDCS. The fact that the changes of NMDA receptors in PAG and spinal cord further confirm that tDCS can exert effects from top to bottom.

Neuroimaging studies have shown that tDCS applied over the primary motor cortex can indirectly activate areas of the brain involved in the modulation of pain perception. Previous studies conceptualized the effect of tDCS, believing that the stimulation of M1 is able to modify activities of cortical (ACC) and sub-cortical (thalamus) regions, and these three regions have direct connections to the spinal cord and are able to alter ascending information at that level. In the spinal cord, this top-down regulation may use different mechanisms, such as local circuits involving presynaptic (primary afferents) and postsynaptic sites (second order neurons), intrinsic inter-neurons, or interconnections between different ascending and descending pathways. Combined with previous studies, we believed that the top-down regulatory mechanism of tDCS may be that changes in the top of the CNS and neurotransmitters indirectly affect the corresponding changes in the bottom of the CNS, which promotes the endogenous analgesic system to exert analgesic effects.

Our results further confirmed the possible mechanism of tDCS top-down regulation and provided new evidence for the existence of tDCS top-down regulation. We suggest that tDCS may play a key role in the top-down modulation of endogenous analgesic system. There are limitations inherent to the current study design and that several questions remain open. More research will be done in the future to explore how tDCS causes NMDA receptor changes at the different level.

Conclusion
This research demonstrated that tDCS can attenuate OA-induced chronic pain in rats via reducing NMDAR2B expressions in the spinal cord. We believe that this may be the result of tDCS participating in the top-down modulation of the endogenous analgesic system. More research is needed to confirm our conclusions in the future.

**Declarations**

**Acknowledgements**

Authors have obtained permission to acknowledge from all authors.

**Funding**

Not applicable.

**Author information**

Authors and Affiliations

Department of Rehabilitation Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.

Xinhe Li, Zhe Liu, Fei Mao, Yan Li, Xiaoning Di, Cuixia Shang, Jin Qiao

Department of Rehabilitation Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.

Xinhe Li

Contributions

JQ and CS designed the study. XL executed the study. ZL acquired the data, FM interpreted the data, YL and XD analyzed the data. All authors contributed to the article and approved the submitted version.

Corresponding authors

Correspondence to Cuixia Shang and Jin Qiao.

**Ethics declarations**

Ethics approval and consent to participate

All experimental methods and procedures were approved by the Animal Experimental Ethics Inspection of Qingdao University (The approval number: NO. 20200901SD4520210601004), in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH...
publication no.85-23, revised 1996). I confirmed the study is reported in accordance with ARRIVE guidelines.

Consent to publish

Not applicable.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

**Availability of Data and Materials**

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

**Supplementary Information**

Additional file 1.

**References**


**Figures**

![Figure 1](image.png)

**Figure 1**

Experimental design (MIA: Monosodium Iodoacetate tDCS: transcranial direct current stimulation IHC-P: Immunohistochemistry-Paraffin sections)
Figure 2

A-B: Effects of tDCS on mechanical allodynia (presented by PWT) and thermal hyperalgesia (presented by PWL) in MIA-induced chronic pain rats were shown in the figure. Compared with the Sham group, there were significant decreases on PWT and PWL after MIA injection. Data were presented as the mean ± SEM, (n=6/group). ****P<0.0001 represented comparison of MIA with Sham group.

Figure 3

A-B: After tDCS treatment, PWT and PWL dramatically increased compared with the MIA group, but no difference was observed between the MIA and MIA+StDCS groups. Data were presented as the mean ± SEM, (n=6/group). ##P<0.01, ###P<0.001, ####P<0.0001 represented comparison of MIA+tDCS with MIA group.
Figure 4

A: Effect of MIA on NMDAR2B protein in the spinal cord by western blot analysis. Data were presented as the mean ± SEM (n=3/group). ****P<0.0001, represented comparison of 7 days, 14 days and 21 days after MIA injection with 1 day before MIA injection.

B: The expression of NMDAR2B protein in the spinal cord was measured at 14 days after tDCS treatment. Data were presented as the mean ± SEM (n=3/group). ****P<0.0001, MIA group vs. Sham group; ##P<0.01, MIA+tDCS group vs. MIA group.
Figure 5

Immunohistochemical staining for NMDAR2B in all groups. Scale bars: 200 µm. The proportion of positive stained cells were presented as the mean ± SEM (n=4/group). ****P<0.0001, MIA group vs. Sham group; ##P<0.01, MIA+tDCS group vs. MIA group.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryInformationfile.pdf